Abstract
We recently demonstrated that the administration of probiotics resulted in a significantly reduced occurrence of atopic dermatitis in infants with high allergic risk. Therefore, the underlying immunological effects that are associated with these apparent clinical benefits were determined. In a randomized, double-blind, placebo-controlled trial, the pregnant women and their infants with a family history of allergic diseases were supplemented with either probiotics (mixture of Bifidobacterium bifidum BGN4, Bifidobacterium lactis AD011, and Lactobacillus acidophilus AD031) or placebo once daily from 4–8 weeks before delivery to 6 months of infants’ age. At 1 year of age, the levels of transforming growth factor (TGF)-β produced by peripheral blood monuclear cells from infants fed probiotics were significantly increased compared with those from infants fed placebo (p=0.042). Thus, reduction of atopic dermatitis prevalence with probiotics supplementation was associated with significant increases in the capacity of TGF-β responses.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Korean Society for Applied Biological Chemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
